Altos Labs, backed by $3 billion from Jeff Bezos and others, has snagged a small Peninsula company focused on one approach to stopping aging ...

Altos Labs just redefined big in biotech. Where to start? The $3 billion in investor support? The C-suite staffed by storied leaders—Barron, Bishop, Klausner—identifiable by one name?

Altos’ recruiting power is evidenced by the ... its global development capabilities with BioNTech, a small German biotech, with a novel mRNA vaccine. Innovation Models Matter The scale of ...

Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according ...

Little is known about Altos, beyond its prestigious leadership ... Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he began 2021 was a “breakout year ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...

Altos Labs, a life sciences startup with a mission to “reverse disease, injury, and the disabilities that can occur throughout life,” officially launched this week, boasting an international ...

Picture: Natalie Behring/Wall Street Journal Arch is the largest institutional investor in Altos, which already has $3 billion of committed investments, likely making it the biotech industry’s ...

The investment firm Robert Nelsen co-founded in 1986, Arch Venture Partners, has racked up billions in profits from early stakes in companies developing methods to detect and treat cancer and ...